“Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials”, J of Skin, vol. 7, no. 2, p. s129, Mar. 2023, doi: 10.25251/skin.7.supp.129.